Quantcast

Anika Therapeutics Inc. (ANIK) Is Sinking On Phase 3 Study Results


Shutterstock photo


(RTTNews.com) - Anika Therapeutics Inc. ( ANIK ) announced after the bell Tuesday that its Phase 3 study of CINGAL 16-02 in patients with knee osteoarthritis failed to reach statistical significance in terms of the primary endpoint.

Anika Therapeutics gapped open sharply lower Wednesday morning and is now down 15.19 at $30.92 on strong volume. The stock has dropped to a new low for the year.


Read the original article on RTTNews (http://www.rttnews.com/2906882/anika-therapeutics-inc-anik-is-sinking-on-phase-3-study-results.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks , Technology
Referenced Symbols: ANIK



More from RTT News

Subscribe






See All RTT news









Research Brokers before you trade

Want to trade FX?